Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Colorcon
Harvard Business School
Dow
Medtronic

Last Updated: November 27, 2022

Doxazosin mesylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for doxazosin mesylate and what is the scope of freedom to operate?

Doxazosin mesylate is the generic ingredient in three branded drugs marketed by Viatris, Accord Hlthcare, Actavis Elizabeth, Ani Pharms, Apotex, Aurobindo Pharma Usa, Chartwell Rx, Genpharm, Heritage Pharma, Ivax Sub Teva Pharms, Nesher Pharms, Pharmgen, Pliva, Strides Pharma, Teva, Upsher Smith Labs, Watson Labs Inc, and Zydus Pharms, and is included in twenty NDAs. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for doxazosin mesylate. Twenty-five suppliers are listed for this compound.

Drug Prices for doxazosin mesylate

See drug prices for doxazosin mesylate

Drug Sales Revenue Trends for doxazosin mesylate

See drug sales revenues for doxazosin mesylate

Recent Clinical Trials for doxazosin mesylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
University of MinnesotaPhase 2

See all doxazosin mesylate clinical trials

Pharmacology for doxazosin mesylate
Medical Subject Heading (MeSH) Categories for doxazosin mesylate

US Patents and Regulatory Information for doxazosin mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075536-002 Oct 18, 2000 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Teva DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075353-004 Jan 12, 2001 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Chartwell Rx DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075646-001 Oct 18, 2000 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Accord Hlthcare DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 202824-001 Jun 11, 2014 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Zydus Pharms DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 208719-004 Jul 7, 2017 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for doxazosin mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viatris CARDURA XL doxazosin mesylate TABLET, EXTENDED RELEASE;ORAL 021269-002 Feb 22, 2005 See Plans and Pricing See Plans and Pricing
Viatris CARDURA doxazosin mesylate TABLET;ORAL 019668-003 Nov 2, 1990 See Plans and Pricing See Plans and Pricing
Viatris CARDURA doxazosin mesylate TABLET;ORAL 019668-004 Nov 2, 1990 See Plans and Pricing See Plans and Pricing
Viatris CARDURA doxazosin mesylate TABLET;ORAL 019668-002 Nov 2, 1990 See Plans and Pricing See Plans and Pricing
Viatris CARDURA doxazosin mesylate TABLET;ORAL 019668-001 Nov 2, 1990 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Dow
Harvard Business School
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.